An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

NCT07807969 · tracked via the Priya Life Science USA tracker

Sponsor

Annexon, Inc

Phase

Phase 3

Started

2026-09-30

Last updated

2026-09-08

Condition(s) studied

Geographic Atrophy

Investigational drug(s) / intervention(s)

Vonaprument →

Vonaprument: Form: solution for injection; Route of Administration: IVT injection

Study summary

The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at/before the ARCHER II Month 24 Visit. Exclusion Criteria: * Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.

Primary outcome measure(s)

Number of Participants with Treatment Emergent Adverse Events — Through Month 24

Trial sites (7)

Facility	City	Region
Retina Group of Florida	Sarasota	Florida
Retina Vitreous Associates of Florida	St. Petersburg	Florida
Cumberland Valley Retina Consultants	Hagerstown	Maryland
Mid Atlantic Retina Specialists	Hagerstown	Maryland
Retina Research Institute at New England Retina Consultants	Springfield	Massachusetts
Asheville Eye Associates - Retina Division	Asheville	North Carolina
Verum Research, LLC	Eugene	Oregon

More Annexon, Inc. trials in the USA

An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) Recruiting

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Active, not recruiting

Other trials for the same condition

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Active, not recruiting

Phase 1 Study of C.001 in Retinal Degeneration Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy Active, not recruiting

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07807969 on ClinicalTrials.gov ↗ ← All trials in the USA